Biocon Biologics

Biocon Biologics, a leading player in the global biopharmaceutical space, has appointed Deepali Naair as the Head of Brand and Corporate Communications. With this strategic hire, the company aims to elevate its global brand visibility and strengthen its narrative in a competitive and rapidly evolving sector. Naair brings a wealth of experience in marketing, digital strategy, and corporate reputation management, having previously led brand mandates across financial services, technology, and consumer sectors.

In a strategic move marking its growing global footprint in biologics, Biocon Biologics Ltd, a subsidiary of Biocon Ltd, has received marketing authorization from the European Commission for Vevzuo and Evfraxy, two biosimilar versions of Denosumab. These biosimilars, used in the treatment and prevention of various bone-related conditions, represent Biocon’s foray into the bone health therapeutic segment and underscore its scientific depth in complex biologics.

Biocon Biologics, a subsidiary of Biocon Ltd, has secured a pivotal approval from the U.S. Food and Drug Administration (USFDA) to market Jobevne, a biosimilar version of Bevacizumab, in the United States. This move marks the company's seventh biosimilar approval in the U.S., underlining its growing global presence in oncology therapeutics. Jobevne, modeled after the blockbuster cancer drug Avastin, is designed to combat various tumors by inhibiting angiogenesis. With this latest milestone, Biocon strengthens its foothold in the USD 2 billion U.S.